logo-loader

OxSonics Therapeutics

Receive alerts
Market:
Unlisted
Market Cap:
-
Price
-
Change
-
52 weeks high
-
52 weeks low
-

In brief

OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers.